On February 26, CR Sanjiu acquired 97.18% of the shares of Guilin Tianhe Pharmaceutical Co., Ltd. at a consideration of 583,100,300 RMB yuan, making Tianhe Pharmaceutical a subsidiary of CR Sanjiu. The acquisition was intended to implement the development strategy of CR Sanjiu, constantly enrich the product line and expand the scope of the orthopedics business.

It is reported that Guilin Tianhe Pharmaceutical Co., Ltd. is one of China's largest external application medicine producer and the only one included in the list of enterprises entitled “Model Modern Project for the Hi-tech Industrialization of Chinese Medicine”. As a well-known Chinese medicine brand, Tianhe has a strong influence in the field of orthopedics. Its core product, Tianhe Gutong Tiegao, is the best brand among the external application medicines for hyperostosis and Tianhe Zhuifengao has a sound standing on the sub-market of medicine for osteoarthritis.